Follow us on social


Biden takes a vital step on vaccine patents — but more action is needed

U.S. support for a patent waiver must be coupled with technology transfers, information sharing, and a coordinated global effort to distribute vaccines.

North America

The Biden administration’s announcement that it will support a WTO patent waiver for COVID-19 vaccines is a welcome step towards ending the global pandemic — but it must be followed by coordinated efforts to boost vaccine production through technology transfer, information sharing, and increased financing to have its promised effect.

The move is a heel-turn for the administration, which in March helped block a proposal led by India and South Africa to waive patents for Covid vaccines, treatments, and vital medical supplies in order to enable the production of affordable generics, particularly in the developing world.

This reversal, announced by U.S. Trade Representative Katherine Tai, comes after months of pressure from activists and public health experts around the globe.

U.S. support does not itself guarantee passage of a patent waiver, as the United States was previously joined in blocking the measure by the United Kingdom, the European Union, and a handful of other countries. It does, however, make it vastly more likely that remaining holdouts will shift their positions. (At this time, New Zealand has already suggested it will move to support the waiver).

While the administration’s announcement is undoubtedly good news, crucial questions remain. Notably, Tai’s statement does not say that the U.S. will support the specific proposal put forward by India and South Africa. This suggests that the United States may advocate for a modified or narrower plan in WTO negotiations. Tai’s announcement states only that the U.S. will support a waiver for vaccines, not for treatments and medical supplies as included in the earlier proposal. To maximize the benefits of a waiver, the Biden administration must be pushed to support the broadest possible proposal, ideally including COVID treatments and medical supplies.

Most importantly, the waiver will require follow-on action in the form of technology transfer and information sharing. While patents are a primary barrier to broader vaccine production, new manufacturers will also need access to key technologies and production information. 

The Biden administration should begin working now to facilitate technology transfer through the World Health Organization’s COVID-19 Technology Access Pool and to share manufacturing information held by Pfizer, Moderna, and others. It should also come up with a plan to finance scaled-up production and distribution of vaccines worldwide.

The administration cannot hesitate in taking these next steps. Its embrace of a patent waiver offers an unprecedented opportunity to bring a more swift end to the pandemic — and with cases surging in devastating outbreaks around the world, there is no time to spare.

North America
Ukraine-Poland row exposes history, limits of devotion
Credit: Polish President Andrzej Duda (Shutterstock/BikerBarakuss) and Ukraine President Volodymyr Zelensky (Shutterstock/Oleksandr Osipov)

Ukraine-Poland row exposes history, limits of devotion


The vitriolic dispute between Poland and Ukraine brings out some aspects of the West’s approach to the war in Ukraine that the Ukrainian government would do well to study carefully.

The dispute originated in charges by Poland and other central European governments that Ukraine’s greatly increased grain exports to Europe — a consequence of the Russian closure of the Black Sea to Ukrainian maritime trade — were flooding European markets and depressing prices for Polish and other farmers.

keep readingShow less
Rep. Gerry Connolly

Rep. Gerry Connolly, screengrab via

How members of Congress can take on Iran hawks

Middle East

During a recent House hearing on “Iran’s escalating threats,” a Democratic lawmaker completely dismantled all the myths opponents of diplomacy peddle about Iran and its nuclear program.

The hearing was dominated by hawkish voices on Iran, who urged for increasing pressure and spurned any diplomatic engagement. The only exception was Suzanne Maloney from the Brookings Institute, who took a more moderate stance.

keep readingShow less
Wall Street Journal

Editorial credit: monticello /

WSJ conceals Saudi funding of pro-Saudi nuke deal source


The Wall Street Journal reported on Thursday that “Israeli officials are quietly working with the Biden administration on a polarizing proposal to set up a U.S.-run uranium-enrichment operation in Saudi Arabia as part of a complex three-way deal to establish official diplomatic relations between the two Middle Eastern countries,” according to U.S. and Israeli officials.

The article, authored by Dion Nissenbaum and Dov Lieber, largely showcases Israeli opposition to the deal. Mark Dubowitz, CEO of the Foundation for Defense of Democracies, a group whose mission includes providing “education to enhance Israel’s image in North America…” was quoted opposing a uranium enrichment program on Saudi soil. He warned that “we’re one bullet away from a disaster in Saudi Arabia,” adding, “What happens if, God forbid, a radical Islamist leader takes control?”

keep readingShow less

Ukraine War Crisis